Table 1.
Patterns of serum antibodies following pediatric GII.17 infections.
Subject ID | ORF1/2 sequencing from stool | Post-infection serum antibodies1 | |||
Binding | Blockade | ||||
Specificity | EC50 titer2 | Specificity | IC50 titer3 | ||
62 | II | I,II, IIIb | 287,210,150 | I | 979 |
132 | II | I,II, IIIb | 481,389,406 | I | 479 |
317 | II | I,II, IIIb | 235,192,113 | I | 460 |
208 | IIIb | I,II, IIIb | 350,281,554 | IIIb | 625 |
263 | IIIb | I,II, IIIb | 292,518,1252 | IIIb | 2974 |
369 | IIIb | I,II, IIIb | 563,332,1502 | I, IIIb | 406, 7290 |
434 | IIIb | I,II, IIIb | 333,357,366 | I, IIIb | 500, 1843 |
1Sera were collected at different times post infection which limits direct comparisons between subjects and may impact the relative titer between clusters as other infections may have occurred prior to GII.17 infection and between the symptomatic GII.17 infection and follow up sera collections.
2Binding titers with respect to indicated specificities. Value indicated is reciprocal of the serum dilution at half maximum binding (50% effective concentration, EC50) for EIA. Assay cutoff is EC50 < 50.
3Blockade titers with respect to indicated specificities. Value indicated is reciprocal of the serum dilution at half maximum blockade activity (50% inhibitory concentration, IC50). Assay cutoff is IC50 < 20.